Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

208 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Myeloma of the central nervous system: association with high-risk chromosomal abnormalities, plasmablastic morphology and extramedullary manifestations.
Fassas AB, Muwalla F, Berryman T, Benramdane R, Joseph L, Anaissie E, Sethi R, Desikan R, Siegel D, Badros A, Toor A, Zangari M, Morris C, Angtuaco E, Mathew S, Wilson C, Hough A, Harik S, Barlogie B, Tricot G. Fassas AB, et al. Among authors: toor a. Br J Haematol. 2002 Apr;117(1):103-8. doi: 10.1046/j.1365-2141.2002.03401.x. Br J Haematol. 2002. PMID: 11918539 Free article. Review.
Preceding chemotherapy, tumour load and age influence engraftment in multiple myeloma patients mobilized with granulocyte colony-stimulating factor alone.
Desikan KR, Tricot G, Munshi NC, Anaissie E, Spoon D, Fassas A, Toor A, Zangari M, Badros A, Morris C, Vesole DH, Siegel D, Jagannath S, Barlogie B. Desikan KR, et al. Among authors: toor a. Br J Haematol. 2001 Jan;112(1):242-7. doi: 10.1046/j.1365-2141.2001.02498.x. Br J Haematol. 2001. PMID: 11167811 Free article.
High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions.
Badros A, Barlogie B, Morris C, Desikan R, Martin SR, Munshi N, Zangari M, Mehta J, Toor A, Cottler-Fox M, Fassas A, Anaissie E, Schichman S, Tricot G. Badros A, et al. Among authors: toor a. Blood. 2001 May 1;97(9):2574-9. doi: 10.1182/blood.v97.9.2574. Blood. 2001. PMID: 11313244 Free article. Clinical Trial.
Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications.
Zangari M, Saghafifar F, Anaissie E, Badros A, Desikan R, Fassas A, Mehta P, Morris C, Toor A, Whitfield D, Siegel E, Barlogie B, Fink L, Tricot G. Zangari M, et al. Among authors: toor a. Blood Coagul Fibrinolysis. 2002 Apr;13(3):187-92. doi: 10.1097/00001721-200204000-00003. Blood Coagul Fibrinolysis. 2002. PMID: 11943931 Clinical Trial.
Infection--an underappreciated cause of bone pain in multiple myeloma.
Desikan R, Barlogie B, Sethi R, Toor A, Spoon D, Angtuaco E, Vanhemert R, VijayaGopal A, Singhal S, Mehta J, Jagannath S, Munshi N, Zangari M, Fassas A, Tricot G, Anaissie E. Desikan R, et al. Among authors: toor a. Br J Haematol. 2003 Mar;120(6):1047-50. doi: 10.1046/j.1365-2141.2003.04178.x. Br J Haematol. 2003. PMID: 12648075 Free article.
208 results